Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Evolus, Inc. | 86,887 | reported | 17 Feb 2026 | tx 19+223,254−20,674 |
| ELECTRO OPTICAL SCIENCES INC /NY | 64,694 | reported | 22 Nov 2019 | tx 3+76,264 |
| CEMPRA, INC. | 30,000 | reported | 11 Jun 2019 | tx 11+174,100 |
| Ocugen, Inc. | 25,000 | reported | 15 Jun 2018 | tx 9+94,000 |
| LEMAITRE VASCULAR INC | 7,500 | reported | 18 Jul 2007 | tx 6+14,305 |
| NxStage Medical, Inc. | 7,442 | reported | 10 May 2006 | tx 1+7,422 |
| Y-mAbs Therapeutics, Inc. | 0 | reported | 16 Sept 2025 | tx 29+164,850−186,850 |
| ISOTIS INC | 0 | reported | 29 Oct 2007 | tx 1−5,000 |
| EndoChoice Holdings, Inc. | 0 | reported | 22 Nov 2016 | tx 10+161,706−250,085 |
| Strongbridge Biopharma plc | 0 | reported | 05 Oct 2021 | tx 8+138,000−138,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 17 Feb 2026 | GRANT_AWARD | Evolus, Inc. | 45,559 | 0.00 USD | |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 5,825 | 8.60 USD | |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 25,080 | — | |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 14,545 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 33,450 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 16,000 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 13,950 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 16,000 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 11,000 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 11,000 | — | deriv |
| 16 Sept 2025 | OTHER | Y-mAbs Therapeutics, Inc. | 24,000 | — | deriv |
| 30 Jun 2025 | GRANT_AWARD | Y-mAbs Therapeutics, Inc. | 25,080 | 0.00 USD | |
| 30 Jun 2025 | GRANT_AWARD | Y-mAbs Therapeutics, Inc. | 33,450 | 0.00 USD | deriv |
| 07 Mar 2025 | GRANT_AWARD | Evolus, Inc. | 7,364 | 0.00 USD | |
| 07 Mar 2025 | GRANT_AWARD | Evolus, Inc. | 11,146 | 0.00 USD | deriv |
| 11 Jun 2024 | GRANT_AWARD | Y-mAbs Therapeutics, Inc. | 3,495 | 0.00 USD | |
| 11 Jun 2024 | GRANT_AWARD | Y-mAbs Therapeutics, Inc. | 14,545 | 0.00 USD | deriv |
| 13 May 2024 | SALE | Evolus, Inc. | 3,643 | 12.72 USD | |
| 14 May 2024 | SALE | Evolus, Inc. | 6,718 | 12.60 USD | |
| 07 Feb 2024 | GRANT_AWARD | Evolus, Inc. | 6,464 | 0.00 USD | |
| 07 Feb 2024 | GRANT_AWARD | Evolus, Inc. | 9,377 | 0.00 USD | deriv |
| 08 Jun 2023 | GRANT_AWARD | Y-mAbs Therapeutics, Inc. | 2,330 | 0.00 USD | |
| 08 Jun 2023 | GRANT_AWARD | Y-mAbs Therapeutics, Inc. | 13,950 | 0.00 USD | deriv |
| 27 Jan 2023 | GRANT_AWARD | Evolus, Inc. | 8,293 | 0.00 USD | |
| 27 Jan 2023 | GRANT_AWARD | Evolus, Inc. | 11,789 | 0.00 USD | deriv |
2 purchases reported after at least 12 months of silence — most recent on 24 Sept 2020.